Evidence map›Paper›PMID 42297787›Full record

ArticleNature communications2026

TASP1-mediated cleavage of REV3L enhances the activity of DNA polymerase ζ in mammalian cells.

Jordane Goulas, Basile Guignier, Barbara Ben Yamin, Caroline Pouvelle, Andrey Yurchenko, Emmanuelle Despras, Luciana de Oliveira, Pierre Laplante, Dorian Bochaton, Damien Plassard and 7 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jordane Goulas *Université Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.
Basile Guignier *Université Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0009-0008-2715-820X
Barbara Ben Yamin *Université Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.
Caroline PouvelleUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.
Andrey YurchenkoUniversité Paris-Saclay, INSERM U981, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-2239-6902
Emmanuelle DesprasUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0003-3331-1748
Luciana de OliveiraUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.
Pierre LaplanteUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.
Dorian BochatonUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0009-0006-5390-9500
Damien PlassardUniversité de Strasbourg, GenomEast Platform - IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire CNRS UMR7104, Inserm U1258, Illkirch, France.
Wei YangLaboratory of Molecular Biology, NIDDK, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3591-2195
François-Xavier TheilletUniversité Paris-Saclay, Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Gif-sur-Yvette, France.ORCID http://orcid.org/0000-0002-3264-210X
Xavier VeauteUniversité de Paris Cité and Université Paris-Saclay, CIGEx Platform, UMR Stabilité Génétique Cellules Souches et Radiations, IRCM/IBFJ CEA, INSERM, Fontenay-aux-Roses, France.ORCID http://orcid.org/0000-0003-4868-247X
Richard D WoodDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9495-6892
Sergey NikolaevUniversité Paris-Saclay, INSERM U981, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-8587-2307
Agnès M CordonnierUniversité de Strasbourg, Biotechnologie et Signalisation Cellulaire, UMR7242, CNRS, Illkirch, France.
Patricia L KannoucheUniversité Paris-Saclay, CNRS-UMR9019 Genome Integrity and Cancers, Gustave Roussy, Villejuif, France. patricia.kannouche@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-6050-3457

Funding

Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research) ARCPGA12019120001055_1578Institut National Du Cancer (French National Cancer Institute) PLBio 2019-152
6 · The paper itself

Abstract

DNA polymerase ζ (Polζ) is essential for replication across damaged DNA, yet the mechanisms governing its regulation in mammalian cells remain incompletely understood. The catalytic subunit REV3L is nearly twice the size of its yeast counterpart owing to a large vertebrate-specific insertion, and recent studies reported that REV3L undergoes proteolytic cleavage by the endopeptidase TASP1. Here, we show that REV3L cleavage generates two stable fragments, Nter-p70 and Cter-p300, which reassociate into a long-lived heterodimeric complex with enhanced polymerase activity. This interaction is stabilized by key residues within the catalytically inactive EXO domain. The cleaved Polζ complex associates with chromatin, binds nascent DNA, and undergoes ATR-dependent phosphorylation in response to replication stress. Importantly, preventing REV3L cleavage markedly impairs Polζ activity, reduces cisplatin-induced mutagenesis, and increases RAD51 nuclear foci and sister chromatid exchange, consistent with a compensatory shift toward homologous recombination-mediated repair. Together, our findings suggest that the vertebrate-specific expansion of REV3L necessitated cleavage to restore structural organization and optimize catalytic function, representing an evolutionary adaptation in DNA damage tolerance pathways.

Indexed as

DNA-Binding ProteinsDNA-Directed DNA PolymeraseAnimalsChromatinCisplatinDNA DamageDNA Damage ToleranceDNA ReplicationHEK293 CellsHumansPhosphorylationProteolysisRad51 RecombinaseTranslesion DNA SynthesisChromatinCisplatinDNA-Binding ProteinsDNA-Directed DNA PolymeraseDNA polymerase zetaRad51 RecombinaseREV3L protein, humanSPRTN protein, human

Identifiers

PMID42297787
PMCPMC13408197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.